Neonatal Atrial Flutter
Atrial flutter is recognized as an uncommon yet potentially fatal rhythm abnormality even in the fetus and neonatal stages. Protheragen is a preclinical research company focusing on rare cardiovascular diseases, particularly atrial flutter. We focus on providing a fully integrated solution that fosters innovation and streamlines processes with the realization of the scientific outcome for the atrial flutter drug development and discovery processes.
Introduction to Neonatal Atrial Flutter
Atrial flutter is recognized as a rare type of arrhythmia in a fetus or neonate, and it belongs to the supraventricular tachyarrhythmias. In the ECG tracing, there is a rapid and disorganized activity of the atrium at a range of 280-500 beats per minute. Atrial flutter may eventually lead to circulatory failure, and in more severe cases, it may cause non-immune fetal hydrops. Mortality owing to perinatal atrial flutter is about 9%.
Fig.1 Performance of individuals with atrial flutter. (Kim, S. J., et al., 2023)Pathogenesis of Neonatal Atrial Flutter
Atrial flutter represents almost one-third of fetal tachyarrhythmias. This arrhythmia results from re-entry circuits confined to the right atrium. The underdeveloped cardiac conduction system in neonates alongside the electrophysiologic characteristics of a developing heart may favor the formation of these reentrant circuits. It is encountered primarily in children with congenital heart defects, but may also occur in individuals with otherwise normal cardiac architecture.
Fig.2 Twin fetal heart rate and serum digoxin levels during therapy. (Kim, S. J., et al., 2023)Therapeutics Development for Neonatal Atrial Flutter
| Drug Names | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|
| Sotalol | A potassium-channel blocking non-selective beta-blocker. | β-adrenoceptors | Phase III |
| Digoxin | Inhibits Na-K ATPase enzymes reversibly, controls ventricular response rates, and improves cardiac output. | Na/K-ATPase | Phase III |
| Flecainide | Interacts with fast-inward Na+ ion channels are high affinity to activated or open Na+ channels. | SCNA | Phase III |
| Diltiazem | A blood vessel relaxer that improves blood flow and is a calcium channel blocker. | VDCCs | Phase IV |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.
Our Services
The services offered by our company include cutting-edge diagnostic development services, custom therapeutic development services as well as complex disease model development. We offer services in preclinical phases which include detailed pharmacokinetics studies and comprehensive drug safety evaluations. By fusing modern engineering with scientific knowledge, we provide solutions that promote the rapid development of therapy innovations.
Therapeutic Development Services
Animal Model Development for Neonatal Atrial Flutter
For the exploration of underlying biological mechanisms and intervention strategies, animal models provide a reliable platform for research. Our firm provides custom services for the development of an animal model for atrial flutter to suit the requirements of your research and development program while expediting translational research.
Ethanol-induced models take advantage of the cytotoxic effects of ethanol to generate controlled chemical injury within the atrial tissue.
- "Y"-shaped lesion model
- Sterile pericarditis model
- Intercaval mechanical crush model
At Protheragen, we blend innovation and precision. Striving toward maintaining the highest quality outcomes, we utilize state-of-the-art research tools and advanced approaches to respond to the challenges of neonatal atrial flutter and other uncommon cardiovascular diseases. For any inquiries, please do not hesitate to reach out.
References
- Kim, Soo Jung et al. "What Is the Optimal Digoxin Level? Challenging Case of Fetal Atrial Flutter Treatment in a Monochorionic Diamniotic Twin." Medicina (Kaunas, Lithuania) 59.7 (2023): 1198.
- Wójtowicz-Marzec, Monika et al. "Successful treatment of neonatal atrial flutter by synchronized cardioversion: case report and literature review." BMC pediatrics 20.1 (2020): 370.
For research use only, not for clinical use.